five

An Open-Label, Dose-Escalation, Phase 1 Study of IXAZOMIB (MLN9708), A Second-Generation Proteasome Inhibitor, in Adult Patients With Lymphoma

收藏
DataCite Commons2025-10-01 更新2026-05-07 收录
下载链接:
https://search.vivli.org/doiLanding/studies/00007107/isLanding
下载链接
链接失效反馈
官方服务:
资源简介:
This study is an open-label, multicenter, phase 1, dose-escalation study of IXAZOMIB in adult patients with lymphoma. This study will be the first to administer IXAZOMIB to patients with lymphoma.
提供机构:
Vivli
创建时间:
2021-05-06
二维码
社区交流群
二维码
科研交流群
商业服务